StockData

Translational Development Acquisition Corp. (TDAC) stock

TDACNasdaqBlank ChecksFiscal year ends December 31Also trades as TDACU, TDACW
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 5/30
$10.88+0.01 (+0.10%)

Close on Nov 18, 2026Market cap $210.09MP/E –Yield –

Translational Development Acquisition operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Translational Development Acquisition's operating income for the twelve months ending Jun 30, 2026 was -$1.32M. For fiscal 2025 it was -$944.54K.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$944.54K–
FY2024Dec 31, 2024-$196.36K–
FY2023Dec 31, 2023-$485.55K–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$661.05K–
Q1 FY2026Mar 31, 2026-$281.16K–
Q4 FY2025Dec 31, 2025-$162.35K–
Q3 FY2025Sep 30, 2025-$213.66K–
Q2 FY2025Jun 30, 2025-$221.13K–
Q1 FY2025Mar 31, 2025-$347.41K–
Q4 FY2024Dec 31, 2024-$133.39K–
Q3 FY2024Sep 30, 2024-$61.28K–
Q2 FY2024Jun 30, 2024-$1.69K–
Q1 FY2024Mar 31, 2024$0–

More Translational Development Acquisition figures

See a number that looks wrong?